Abstract Atrial fibrillation (AF) is the most common cardiac arrhythmia, and it causes substantial mortality. The autonomic nervous system, and particularly the adrenergic/cholinergic balance, has a profound influence on the occurrence of AF. exchange, and may also enhance automaticity. Catecholamines might affect reentry, by altering excitability or conduction, rather than action potential terminal repolarisation or refractory period. However, which arrhythmia mechanisms predominate is unclear, and likely depends on cardiac pathology and adrenergic tone. Heart failure (HF), a major cause of AF, causes adrenergic activation and adaptational changes, remodelling, of atrial electrophysiology, Ca 2+ homeostasis, and adrenergic responses. Chronic AF also remodels these, but differently to HF. Myocardial infarction and AF cause neural remodelling that also may promote AF. β-Adrenoceptor antagonists (β-blockers) are used in the treatment of AF, mainly to control the ventricular rate, by slowing atrioventricular conduction. β-Blockers also reduce the incidence of AF, particularly in HF or after cardiac surgery, when adrenergic tone is high. Furthermore, the chronic treatment of patients with β-blockers remodels the atria, with a potentially antiarrhythmic increase in the refractory period. Therefore, the suppression of AF by β-blocker treatment may involve an attenuation of arrhythmic activity that is caused by increased [Ca 2+ ] i , coupled with effects of adaptation to the treatment. An improved understanding of the involvement of the adrenergic system and its control in basic mechanisms of AF under differing cardiac pathologies might lead to better treatments.
Introduction
Atrial fibrillation (AF) is the most common cardiac arrhythmia, with an estimated prevalence in the general population of 0.4-1% (Fuster et al. 2006) . AF affects primarily the elderly, e.g. 4.6% of people aged >65 years and 7.1% of those >85 years (Murphy et al. 2007) . Symptoms include palpitations, dizziness, fatigue, chest pain, and dyspnoea. Moreover, AF substantially increases the risk of stroke, heart failure (HF), and death (Fuster et al. 2006) . Pharmacological therapy is the mainstay of treatment. However, current antiarrhythmic drugs for AF prevention have limited efficacy and considerable potential for adverse effects. The autonomic nervous system has a profound influence on the occurrence of AF, and a predominance of activity of either the adrenergic (sympathetic; Dimmer et al. 1998) or cholinergic (parasympathetic; Bettoni and Zimmermann 2002) branches can promote AF. Furthermore, AF may be generated and maintained by a variety of electrophysiological mechanisms (Workman et al. 2008) , and a change in autonomic activity is expected to affect each differently. This review focuses on the effects of adrenergic stimulation and antagonism on the electrophysiological mechanisms of AF and on their modulation by atrial remodelling from cardiac disease and drug treatment. The effects of adrenergic modulation are wide ranging, complex, and species-and cardiac chamber-dependent, so studies of human atrium are highlighted where available.
The cardiac adrenergic system
The cardiac adrenergic system comprises adrenergic nerves, hormones, and receptors. Preganglionic adrenergic neurons of the spinal cord, sympathetic trunk, cervical ganglia, and cardiac plexuses synapse with postganglionic neurons. Those penetrate the myocardium along coronary arterial pathways, terminating on cardiac myocytes and vessels of all chambers (Kawashima 2005) . Adrenergic stimulation results in the release of the adrenergic hormones, catecholamines, including noradrenaline (norepinephrine) from postganglionic nerve terminals and adrenaline (epinephrine) from the adrenal medulla. Catecholamines bind to and activate cell surface adrenoceptors, including the α, β 1 , β 2 , and β 3 subtypes, all of which are present in human atrium (Mary-Rabine et al. 1978; Hedberg et al. 1985; Chamberlain et al. 1999) . Their independent stimulation has complex and sometimes opposing effects on atrial function, and the net response to catecholamine stimulation depends on catecholamine type and relative adrenoceptor subtype density and sensitivity, which may vary with disease.
What is the evidence for involvement of the adrenergic system in AF?
In patients, heart rate variability studies indicated an increased level of adrenergic, relative to cholinergic, activity in the minutes preceding the onset of AF (Dimmer et al. 1998; Coccagna et al. 1997) . However, increased cholinergic activity, perhaps following increased adrenergic activity (Bettoni and Zimmermann 2002) , also generated AF. Infusion of isoprenaline (isoproterenol, ISO), a mixed β-receptor agonist, produced AF in 5% of patients with no history of AF and in 84% of patients with paroxysmal AF, in a dose-dependent manner (Oral et al. 2008) . In dogs, adrenaline (Sharifov et al. 2004) or ISO (Kiss et al. 2004; Sharifov et al. 2004 ) produced AF, and ISO facilitated acetylcholine-induced AF (Sharifov et al. 2004) . Electrical stimulation of pulmonary vein (PV) autonomic nerves produced rapid PV arrhythmic activation, abolished by the β 1 -antagonist (β 1 -blocker) atenolol (Patterson et al. 2005) . Furthermore, increased atrial adrenergic innervation was associated with chronic AF in patients (Gould et al. 2006) . Propranolol (a mixed β-blocker) reduced the incidence of burst pacing-induced sustained atrial tachyarrhythmia (AT) associated with HF in dogs (Stambler et al. 2003) . Moreover, several β-blockers are effective in suppressing AF in patients with various heart diseases (Lopez- Sendon et al. 2004) . It is reasonable to infer, therefore, that adrenergic stimulation may be involved in the initiation and/or maintenance of AF. However, it is unclear how adrenergic stimulation or antagonism affects the various electrophysiological mechanisms of AF, or indeed, which of these mechanisms predominate.
Electrophysiological mechanisms of AF initiation and maintenance
The majority of atrial premature beats that trigger (initiate) AF originate from focal (focussed) ectopic (away from the sinoatrial (SA) node) electrical activity in or near the PVs. For example, in patients with drug-resistant paroxysmal AF, 94% of ectopic foci that initiated spontaneous AF were located, using multielectrode catheter mapping, to the PVs (Haissaguerre et al. 1998 ). The electrophysiological mechanism of the trigger is often considered to be either abnormal automaticity (AA) or triggered activity. AA is the premature firing of action potentials due to increased pacemaking, i.e. accelerated diastolic, phase 4, membrane depolarisation. It is favoured by an increase in diastolic inward, depolarising, ion currents such as the funny current (I f ) and potentially the L-type Ca 2+ (I CaL ) and Na
exchanger (I Na/Ca ) currents. It is also favoured by a decrease in outward, hyperpolarising, currents such as the delayed rectifier K + currents, of which there are various types, having either ultrarapid (I Kur ), rapid (I Kr ), or slow (I Ks ) activation kinetics. Triggered activity is premature firing due to oscillations in membrane potential following an action potential upstroke, i.e. afterdepolarisations. Those may be delayed (DADs), which occur after full repolarisation. They are favoured by high heart rates and excessive intracellular Ca 2+ (Ca 2+ i ) loading. That can result in a transient inward current carried by I Na/Ca , as one Ca 2+ is extruded in exchange for three Na + . Alternatively, they may be early afterdepolarisations (EADs), which occur during repolarisation. Those are favoured by low heart rates, increases in the action potential duration (APD) in the voltage range at which I CaL can reactivate, or by abnormalities in I Na activation or inactivation. Once initiated, AF may be maintained by single or multiple wavelet intramural reentry. Reentry is rapid circuitous activation caused by unidirectional conduction block. It is favoured by premature beats, increased spatial heterogeneity of electrical activity, and a decrease in the circuit length, the wavelength. For example, a premature impulse may divide at a functional or anatomical obstacle, with one wavefront being blocked at refractory, i.e. inexcitable tissue. The other may activate adjacent tissue with a short effective refractory period (ERP), circulate the obstacle, and reenter the previously inexcitable tissue provided that the wavelength (ERP × conduction velocity) is shorter than the available conduction path (Workman et al. 2008) . A reduced ERP may result from early availability of the Na + channel current (I Na ) due, e.g. to shortening of the terminal phase of repolarisation of the action potential. Slowed conduction may result from decreased excitability, increased intercellular fibrosis, or reduced intercellular gap junction current (I gap ). Myocardial tissue capable of supporting reentry is sometimes termed a reentrant "substrate", i.e. having structural or functional characteristics predisposing to reentry, perhaps resulting from pathological remodelling. It should be noted, however, that a pathological predisposition to sustained nonreentrant activity (AA and/or triggered activity) could also constitute, or contribute to, a substrate for AF. Furthermore, the focal trigger of AF in the PVs could be either microreentrant, triggered, or abnormally automatic (Haissaguerre et al. 1998) . Whether reentrant or nonreentrant mechanisms predominate is under debate (Wit and Boyden 2007) , and likely depends on, e.g. the underlying cardiac pathology and autonomic tone. The effects of changes in adrenergic activity on each of the reentrant and nonreentrant mechanisms should, therefore, be considered when attempting to understand how adrenergic modulation affects the initiation and maintenance of AF.
Effects of adrenergic stimulation on pacemaking
In the natural pacemaker, the SA node, adrenergic stimulation accelerates phase 4, shortening diastole, thus increasing heart rate. Multiple ion current mechanisms have been proposed. In rabbit SA node, β-stimulation increased I f , associated with a positive shift in its activation voltage (Barbuti et al. 2007) , and accelerated the deactivation of I Kr and I KS (Lei et al. 2000) ; each potentially accelerating phase 4. β-Stimulation also increases SA nodal I CaL and peak [Ca 2+ ] i , potentially enhancing phase 4 via increased I Na/Ca (Bers 2008 ). The atrium is not normally a pacemaker, although isolated tissues obtained from patients undergoing cardiac surgery may activate spontaneously. Right atrial (RA) pectinate muscles sometimes featured a "single pacemaker", and adrenaline transiently decreased, then markedly increased, its rate (Trautwein et al. 1962) . Specialised conducting fibres from human RA were identified by their pacemaker activity after ceasing stimulation, and adrenaline increased phase 4 and automatic rate (Mary-Rabine et al. 1978) . A similar effect of adrenergic stimulation was observed in other human studies (Mary-Rabine et al. 1980; Levi et al. 1981) , as well as in healthy animal atria (Davis 1975; Ono et al. 1995) . Specialised pacemaker-type cells, similar to those normally found in SA node, have been identified in patients' PVs (Perez-Lugones et al. 2003) . Pacemaker activity was found in rabbit PV isolated cells, which was enhanced by ISO (Chen et al. 2002) . However, it is unclear whether pacemaking, or AA, occur in either PV or atrium in vivo, or whether such activity could arise from adrenergic stimulation.
Can adrenergic stimulation cause afterdepolarisations in human atrium?
Adrenergic stimulation produces several types of arrhythmic electrical activity in human atrial isolated tissues or cells that are distinct from the production of regular automaticity or the acceleration of automatic rate. In unstimulated, quiescent RA muscle strips, adrenaline produced "bizarre" action potentials of "various shapes, durations and frequencies", some with "distinct second spikes" (Sleator and De Gubareff 1964; Fig. 1a) . ISO produced "DADs" or "triggered activity" in unstimulated RA "specialized fibers" ). Adrenaline produced "DADs" immediately after cessation of physiological rate stimulation in RA trabeculae (Yeh et al. 1992) . In RA isolated cells stimulated at physiological rate, ISO caused action potentials to be interrupted frequently by low amplitude, usually subthreshold, transient depolarisations, termed "cellular arrhythmic depolarisations" (CADs; Redpath et al. 2006; Fig. 1b (Sleator and De Gubareff 1964; a) and with permission from American Physiological Society, and Elsevier, respectively after repolarisation, during repolarisation or after a CAD, and may represent DADs, EADs, or AA. Adrenergic stimulation also produced "arrhythmic contractions" in human RA appendages (Kaumann and Sanders 1993) , although electrical activity was not studied. Therefore, adrenergic stimulation produced arrhythmic electrical activity in each of four studies that could be found on human atrial isolated tissues or cells. For such activity to qualify as a DAD, its amplitude should increase and its coupling interval decrease in proportion with an increasing stimulation rate (Wit and Boyden 2007) , as demonstrated in canine atria with adrenaline (Johnson et al. 1986 ). However, in none of these human atrial studies were potential DADs qualified in that way. Which type of nonreentrant activity is produced by adrenergic stimulation in human atrium remains unclear.
Can adrenergic stimulation affect atrial reentry?
Reported effects of adrenergic stimulation on atrial reentry wavelength are rather discordant. In the absence of arrhythmias, wavelength change has been assessed by measuring ERP and conduction velocity. In patients, intravenous ISO increased wavelength, associated with suppression of extrastimuli-induced repetitive atrial firing, by causing a marked increase in conduction velocity and only a small change in ERP (Shimizu et al. 1994a ). However, an absence of change in atrial wavelength in dogs (Rensma et al. 1988) or an increase due to ERP prolongation in rabbits (Smeets et al. 1986 ) also were reported. In patients with atrial flutter, ISO decreased the arrhythmia cycle length, primarily by slowing conduction, thus potentially promoting reentry (Stambler et al. 1996) . ISO also sustained reentrant circuits in PVs, but without changing conduction velocity (Arora et al. 2003) . In diseased atria that are partially depolarised, adrenergic stimulation might inhibit reentry, by increasing excitability and overcoming conduction block. For example, in tissues from patients with RA enlargement, slow-rate ectopic foci fired independently of the pacing stimuli, revealing conduction block between driven and ectopic cells. Adrenaline hyperpolarised the maximum diastolic potential (MDP) and abolished the ectopic foci by electrically connecting them to the driven cells (Gelband et al. 1977) . However, since adrenergic stimulation increases I CaL , this could potentially promote reentry in tissues which remain sufficiently depolarised to keep I Na inactive, by generating slowly conducted Ca 2+ -dependent action potentials. Atrial reentry and AF can result from wavelength decrease associated with reduction of ERP, as demonstrated with acetylcholine (Rensma et al. 1988) . There are few studies of effects of adrenergic stimulation on human atrial ERP, with a report of a small (5%) decrease (Shimizu et al. 1994a ) and of no change . There are several studies, however, of effects of adrenergic stimulation on human atrial action potential terminal repolarisation, a major determinant of the ERP.
Effects of adrenergic stimulation on human atrial action potentials
Adrenergic stimulation is generally considered to shorten myocardial terminal repolarisation, as shown in canine ventricle, with a reduction in the APD at 95% repolarisation (APD 95 ) in isolated tissues (Volders et al. 2003) and cells (Stengl et al. 2006 ; i in Fig. 2a) . In human ventricle, however, adrenergic stimulation may lengthen, rather than shorten, terminal repolarisation, since, in isolated tissues or cells, APD 95 was markedly prolonged by noradrenaline or ISO in three of four available studies (Eckel et al. 1982; Mitchell et al. 1986; Koumi et al. 1995; ii in Fig. 2a) and by adrenaline in two of three tissues in the other study (Yeh et al. 1992) . It should be noted, however, that these preparations were from patients who were undergoing cardiac surgery, and the associated myocardial diseases and drug treatments could affect the responses to adrenergic stimulation. In undiseased human ventricular tissues, adrenaline had no effect on repolarisation already prolonged by dofetilide (Jost et al. 2005 ), but effects of adrenergic stimulation alone were not studied. In human atrium, by contrast with ventricle, terminal repolarisation is usually unaffected by adrenergic stimulation. Of the six available reports in isolated tissues or cells, five showed no significant effect of adrenaline or ISO on APD 90 (Sleator and De Gubareff 1964; Gelband et al. 1977; Kecskemeti et al. 1985; Yeh et al. 1992; Redpath et al. 2006 ; e.g. iii and iv in Fig. 2a) , and one showed a marked increase in APD 90 (Li and Nattel 1997) . Species differences in effects of adrenergic stimulation on atrial terminal repolarisation should be noted, however, with shortening in dog (Liang et al. 1985; Yeh et al. 2007) , and lengthening in guinea pig (Yoshimoto et al. 1998 ) and rat (Webb and Hollander 1956) . The MDP and action potential maximum upstroke velocity, which can affect conduction velocity and hence reentry, also were unaffected by adrenergic stimulation, in normally polarised human atrial tissues (Gelband et al. 1977; Kecskemeti et al. 1985) . However, the action potential plateau, phase 2, was markedly elevated by adrenergic stimulation in several reports, reflected by increased APD 50 (Kecskemeti et al. 1985; Li and Nattel 1997; Redpath et al. 2006) . For example, 50 nM ISO approximately doubled APD 50 in human atrial cells ; iv in Fig. 2a ). The available human atrial studies, taken together, do not support an effect of adrenergic stimulation that could substantially affect reentry via action potential terminal repolarisation. However, the plateau elevation has the potential to promote afterdepolarisations, either by increasing APD in the voltage range at which I CaL can reactivate and thus cause EADs (Bers 2008) , or by its association with increased Ca 2+ i loading and DADs. To understand the mechanisms by which adrenergic stimulation elevates the action potential plateau, without affecting terminal repolarisation, we need to know which ion currents are affected in human atrium by adrenergic stimulation and also how these currents interact.
Effects of adrenergic stimulation on human atrial ion currents
The atrial action potential plateau amplitude is determined largely by the magnitude of I CaL (Fig. 2b) . This is an inward cationic, i.e. depolarising, current, and its agonism and blockade elevate and lower the plateau, respectively, as shown using Bay K 8644 (Yue et al. 1997) or nifedipine (Workman et al. 2001) . Adrenergic stimulation has consistently been shown to increase human atrial I CaL , often more than twofold, e.g. (Ouadid et al. 1995; Pelzmann et al. 1995; Li and Nattel 1997; Van Wagoner et al. 1999; Christ et al. 2004; Redpath et al. 2006; Greiser et al. 2007; Fig. 2b ). The biophysical mechanism is an increase in the open probability of available I CaL channels, resulting from an increase in their open time and a decrease in their closed time. The signalling mechanism involves phosphorylation of I CaL channels by protein kinase A (PKA). That is activated by increased adenylyl cyclase-dependent cyclic AMP (cAMP), which results from the stimulation of GTP regulatory proteins due to the binding of catecholamines to β-receptors. I CaL may be moderately increased by high stimulation rates, due to slowing of current decay: so-called high frequency-induced upregulation (HFIUR). Since HFIUR was potentiated by ISO in human atrial cells (Piot et al. 1996) , the increase in I CaL by adrenergic stimulation may be potentiated at the high atrial rates encountered during AF. The influence of I CaL on the action potential is normally balanced partly by the transient outward K + current (I TO ). However, I TO was unaffected by ISO in human atrium (Su et al. 1994 ) and should not, therefore, alter the influence of I CaL to elevate the plateau. Chloride currents (I Cl ) also may contribute to early repolarisation. However, ISO had inconsistent effects on human atrial I Cl , with either an increase (Tsai et al. 2001) or no change (Sakai et al. 1995) in I Cl.cAMP , or no change in I Cl.swell (Sato and Koumi 1998) . Reports of effects of adrenergic stimulation on other mechanosensitive currents (Stiber et al. 2009 ) in human atrium could not be found. The increased voltage resulting from the increase in I CaL may enhance the activation of delayed rectifier K + currents, with a potential shortening influence on terminal repolarisation. However, the relative magnitudes and contributions to repolarisation, of I Kur , I Kr , and I KS in human atrium are incompletely understood. I Kr and I KS were relatively small or present in only a minority of cells (Wang et al. 1994;  Species-and cardiac chamber-dependent effects of adrenergic stimulation on action potentials and ion currents. a Action potentials from dog (i) and human (ii) left ventricular myocyte, and from human right atrial tissue (iii) and myocyte (iv). C control, ISO isoprenaline, A adrenaline, W washout, HMR HMR1556 (I KS blocker), ET endothelin. Calibrations: 25 mV, 100 ms. Based on data in (Stengl et al. 2006 ; i), (Koumi et al. 1995 ; ii), (Yeh et al. 1992 ; iii), and ; iv) with permission from Oxford University Press, American Society for Clinical Investigation, S. Karger AG, Basel, and Elsevier, respectively. b Simulated time courses of main human atrial ion currents (defined in text) determining action potential (top trace) shape. Ordinate scales equalised for all currents ≤0.5 pA/pF. All traces derived from mathematical model (Courtemanche et al. 1998 ) using CESE Pro 1.4.8 software (Simulogic Inc., Halifax, Canada). Arrows indicate reported effect of ISO on currents Schaffer et al. 1998) , but this might reflect disruption of these currents by the requisite "chunk" method of cell isolation (Yue et al. 1996) , and in intact atrial tissue, I Kr blockade may prolong APD 90 (Wettwer et al. 2004 ). Adrenergic stimulation may increase both I Kr (Heath and Terrar 2000) and I KS (Volders et al. 2003) , but human atrial data are lacking. Altered plateau voltages resulting from changes in I Kur also may affect terminal repolarisation via I Kr and I KS (Wettwer et al. 2004) , and adrenergic stimulation increased I Kur in human atrium (Li et al. 1996; Su et al. 1994) . Therefore, the net contribution of adrenergic stimulation-induced changes in I Kur , I Kr , and I KS to human atrial terminal repolarisation is unclear. Several additional currents contribute to terminal repolarisation in human atrium, including the inward rectifier K + currents I K1 and I KACh , the Na + , K + pump current (I p ), I Na/Ca , and possibly ATP-sensitive K + current (I KATP ) (Workman et al. 2008) . ISO increased I KACh in canine atrium (Yeh et al. 2007 ), yet it may affect neither I K1 nor I KACh in human atrium (Voigt et al. 2009 ). Human atrial I p has been measured directly in only a single study (Workman et al. 2003a ), but adrenergic stimulation was not studied. However, the hyperpolarisation caused by rewarming of human atrial tissue, considered to be due to I p reactivation, was unaffected by adrenaline (Rasmussen et al. 1985) . I Na/Ca was increased by ISO in cat atrium (Zhou and Lipsius 1993), but human atrial data are lacking. I KATP was increased by ISO in cat ventricle, from ATP i depletion rather than a direct effect (Schackow and ten Eick 1994) , but atrial data are lacking. I Na was reduced by ISO in human atrium (Lee et al. 1990 ). However, any conduction-slowing influence of that might be outweighed by an opposing increase in I gap (Salameh et al. 2006 ). I f is consistently increased by β-stimulation in human atrium, associated with a positive shift in its activation voltage, e.g. (Hoppe and Beuckelmann 1998; Lonardo et al. 2005 ). However, whether such an increase could lead to atrial arrhythmias from AA is uncertain (Workman and Rankin 1998) , because of the rather negative activation voltage of I f relative to atrial MDP, and the small current size under physiological [K + ] o . Mathematical modelling should help to clarify the relative contribution of these ion current changes to the altered action potential shape under adrenergic stimulation. However, the weight of currently available evidence, summarised in Fig. 2b , suggests that, in human atrium, the plateau is elevated primarily by I CaL increase, and that an associated increase in I Kur , with little or no direct effect on other repolarising currents, results in no net change in terminal repolarisation. The contrasting changes in terminal repolarisation seen in some other species and in ventricle may result in part from differing magnitudes of the various delayed rectifier current components. Moreover, the prominent increase in I CaL has important implications for Ca (Walden et al. 2009 ). In human atrial cells, β-stimulation increased the Ca 2+ i transient amplitude (Hatem et al. 1995) , as reported in atria of other species (Mackenzie et al. 2004; Danson et al. 2005; Coutu et al. 2006 ). In rat atrial cells which displayed primarily peripheral Ca 2+ i transients, β-stimulation produced large transients in central regions (Mackenzie et al. 2004 was not studied (Johnson et al. 1986 ). ISO promoted spontaneous Ca 2+ i transients in canine atrial and PV cells, but action potentials were not studied (Coutu et al. 2006) . Focal ectopic beats that were preceded by rises in [Ca 2+ ] i were produced by perfusing canine atria with ryanodine plus ISO, but ISO alone was not studied (Chou et al. 2005 ] i sufficiently to cause DADs or AA, but more studies are required to clarify that.
Independent stimulation of adrenoceptor subtypes
The effects of adrenergic stimulation on atrial rhythm, pacemaking, propensity to spontaneous depolarisations, reentry, and action potentials were demonstrated using both combined β-and α-stimulation with adrenaline, and β-stimulation only, with ISO. Effects of adrenaline and ISO, sometimes compared within studies, largely conformed, suggesting a prominent involvement of β. However, for human atrial ion currents or Ca 2+ i , β-stimulation only was used, except in one study ). Moreover, adrenoceptor subtypes can mediate different, sometimes opposing (Li et al. 1996; Yeh et al. 2007 ) effects that may also vary with cardiac disease. Independent β 1 -and β 2 -stimulation has been studied using ISO plus selective β-subtype blockers. In canine atrium, whilst only ∼25% of β-receptors were β 2 , ∼50% of the effect of ISO to decrease APD 75 was via β 2 (Liang et al. 1985) . In human atrium, however, although up to 55% of β-receptors are β 2 (Hedberg et al. 1985) , ISO did not affect APD 75 . β 2 -Stimulation increased human atrial I CaL (Skeberdis et al. 1997 ) and I f (Lonardo et al. 2005) , although the I f increase was greater with β 1 -than β 2 -stimulation. Nevertheless, the electrophysiological effects of independent β 2 -, or indeed β 1 -, stimulation in human atrium are largely unknown. β 3 -Stimulation had no effect on mouse atrial contraction (Oostendorp and Kaumann 2000) , but no human atrial studies were found. In ventricle, β 3 -stimulation moderately affected APD (Gauthier et al. 1996; Bosch et al. 2002) , probably via I KS (Bosch et al. 2002) which may have limited involvement in human atrium. However, since β 3 -stimulation can affect I K1 (Scherer et al. 2007 ), I CaL , and Ca 2+ i , its potential to contribute to atrial adrenergic electrophysiological responses should not be overlooked. Myocardial effects of α-stimulation are multiple, complex, and species-, chamber-, and α-subtype-dependent. In human atrium, an α-agonist increased APD (Sato and Koumi 1995) . That is consistent with effects of phenylephrine to inhibit I K1 (Su et al. 1994; Voigt et al. 2009 ), I KACh (Voigt et al. 2009 ), and I Kur (Li et al. 1996) . However, the APD increase could also involve an increase in the Ca 2+ i transient (Jahnel et al. 1992) , although data are lacking in human atrium. Furthermore, α-stimulation may increase inositol (1,4,5)-trisphosphate (InsP 3 ), and InsP 3 can cause Ca 2+ i release, particularly in atrium, in which InsP 3 receptors are prevalent (Bers 2002) . However, the rate and extent of Ca 2+ i release is much lower via InsP 3 than CICR (Bers 2002) . α-, by contrast with β-stimulation, did not produce DADs or EADs in canine ventricle (Priori and Corr 1990) , but whether it would in human atrium is unknown.
Heart failure causes AF, atrial remodelling, and sympathetic activation AF is usually associated with cardiac disease, such as coronary artery disease, valve disease, hypertension, myocardial infarction (MI), or HF. These, and AF, can cause chronic adaptational changes, i.e. remodelling, of atrial structure and function, including adrenergic responses, as well as increasing adrenergic tone. Each disease may, therefore, influence an involvement of the adrenergic system in the development of AF in a variety of ways. HF is a major cause of AF, and both systolic and diastolic ventricular dysfunctions were independently associated with increased risk of AF (Tsang et al. 2002) . Severe HF was associated with an ∼70% increase in plasma noradrenaline (Bolger et al. 2002) . However, the maximum concentration reached, 2.7 nM, was ∼75-fold lower than was half maximally effective at increasing I CaL . Therefore, a promotion by HF of adrenergically mediated atrial arrhythmic activity involving, e.g. I CaL increase may require a localised catecholamine accumulation. HF can predispose to atrial arrhythmic activity by remodelling atrial electrophysiology and Ca 2+ i homeostasis. In dogs, chronic ventricular tachypacing-induced congestive HF (CHF) increased atrial ERP and APD and produced spontaneous depolarisations (Stambler et al. 2003; Yeh et al. 2008) . This was associated with various ion current changes including decreased I TO , I CaL , and I KS and increased I Na/Ca , whilst I K1 , I Kr , and I Kur were unaffected (Li et al. 2000 (Eisner et al. 2009 ). Nevertheless, CHF-induced atrial arrhythmic activity may involve RyRs, since it was abolished by RyR blockade in dogs (Stambler et al. 2003; Yeh et al. 2008) . Such arrhythmic activity might be potentiated by increased adrenergic tone, e.g. via increased phosphorylation of I CaL and PLB, although this awaits investigation. Human atrial electrophysiological changes have been associated with CHF or left ventricular systolic dysfunction (LVSD). Whilst the data are often compounded by variability in patients' disease states and drug treatments (Workman et al. 2008) , LVSD has been independently associated with a reduction in the atrial cellular ERP (Workman et al. 2009 ). In that study, the ERP correlated positively with the LV ejection fraction (Workman et al. 2009 ), which is a significant predictor of AF (Tsang et al. 2002) . Such ERP decrease, which contrasts with the ERP increase in canine CHF, might predispose to reentry by decreasing the wavelength. The ionic mechanisms are unclear, although an associated reduction in I TO (Workman et al. 2009 ) might be involved. I K1 , I CaL , and the sustained outward current (I SUS ; predominantly I Kur ) were unaffected. I KS , a likely major contributor to the APD increase in canine CHF, may be minimally involved in human atrium.
Other atrial currents such as I Na/Ca , constitutively active (CA) I KACh , I Na , I p , and stretch-activated currents, as well as Ca 2+ i , and afterdepolarisations, remain to studied in human HF (Workman et al. 2008 ). The expression of atrial HCN2 and HCN4 (encode I f ) was increased in human HF (Stillitano et al. 2008 ), but atrial I f was not measured. Some human atrial responses to adrenergic stimulation have been studied, although the data were equivocal. The effect of ISO to increase I CaL or HFIUR was attenuated (Ouadid et al. 1995; Piot et al. 1996) , unchanged (Workman et al. 2009 ), or potentiated (Dinanian et al. 2008 ) in patients with HF or LVSD, and contractile responses to ISO were attenuated (Harding et al. 1990 ). An attenuated β-response may involve impaired β-receptor function or signalling, or a reduction in receptor density, as shown in atria of patients with end-stage HF (Steinfath et al. 1992) or pigs with CHF (Roth et al. 1993 ). Furthermore, HF may preferentially downregulate β 1 , in atrium, depending on the cause of HF (Steinfath et al. 1992) , and that could result from chronic adrenergic stimulation (Brown et al. 1992) . β 3 density was not studied in atrium, although this was increased in ventricle (Moniotte et al. 2001 ). The multiple, complex, and interacting influences of HF on the involvement of the adrenergic system in the development of AF are, therefore, yet to be resolved.
AF causes AF and atrial remodelling
Once AF occurs, a persistence of the rapid atrial activation causes atrial electrophysiological remodelling that promotes AF. This includes a reduction in the atrial ERP, AF cycle length, and reentry wavelength (Workman et al. 2008) . Chronic AF in patients was associated with a decreased atrial ERP and RA conduction velocity, increased ERP dispersion (Kojodjojo et al. 2007) , and decreased atrial isolated tissue or cellular ERP (Workman et al. 2001) or APD 90 (Bosch et al. 1999; Workman et al. 2001; Wettwer et al. 2004; Pau et al. 2007 ). In dogs, chronic rapid atrial rate also decreased APD 90 in isolated PVs (Chen et al. 2000; Cha et al. 2005) , and either enhanced (Chen et al. 2000) or did not enhance (Cha et al. 2005 ) the ability of PVs to produce arrhythmic activity. The atrial ion current changes are different in chronic AF than in HF or LVSD (Workman et al. 2008 (Workman et al. , 2009 , with an increased I K1 and CA I KACh , and a markedly decreased I CaL and I TO . I p was unchanged (Workman et al. 2003a) ; data on I Kur and I KATP are equivocal; and several other currents remain to be studied (Workman et al. 2008) . These include I Kr and I KS , whose activation could be enhanced by action potential triangulation in chronic AF (Workman et al. 2001) . Rapid atrial rate also remodels Ca i waves was increased in both studies, and Ca 2+ SR content was unchanged. Chronic AF also increased PKA phosphorylation of RyR (Vest et al. 2005) . The effects of adrenergic stimulation on Ca 2+ i were not studied in AF-remodelled atrium. Moreover, AF without HF may not change catecholamine levels in patients (Berglund et al. 1990 ). Nevertheless, chronic AF has consistently been shown to be associated with a potentiated effect of ISO to increase human atrial I CaL (Van Wagoner et al. 1999; Skasa et al. 2001; Christ et al. 2004; Greiser et al. 2007 ). This contrasts with an attenuated effect of 5-hydroxytryptamine (5-HT) on I CaL (Pau et al. 2007) , despite both acting via cAMP. The kinase/phosphatase balance can affect I CaL in human AF without altered channel transcription or translation . Since β-(unlike 5-HT-) receptor expression was unchanged in AF (Grammer et al. 2001) , the potentiated I CaL response to adrenergic stimulation might involve altered signalling, perhaps via CaMKII . Chronic AF was also associated with an attenuated effect of α-stimulation to decrease human atrial I K1 and I KACh (Voigt et al. 2009 ). The lack of change in atrial Ca 2+ SR content associated with chronic AF, in contrast to the increase by HF, might suggest a lower susceptibility to any adrenergically mediated arrhythmic activity than in HF. However, that remains to be investigated. Furthermore, AF remodelling may interact with HF remodelling (Workman et al. 2008) , but no studies of adrenergic stimulation in that setting could be found.
Atrial neural remodelling by MI and by chronic AF
Atrial adrenergic nerves can be modified by myocardial diseases associated with AF, and also by persistent rapid atrial activation, so-called neural remodelling. For example, ventricular MI in dogs increased the atrial density and spatial heterogeneity of both tyrosine hydroxylase, which stains adrenergic nerves, and growth-associated protein, which stains for nerve sprouting, or axonal regeneration. This may have resulted from injury of atrial nerves passing through the ventricle (Miyauchi et al. 2003) . Chronic AT in dogs caused a spatially heterogeneous atrial adrenergic hyperinnervation, an increased atrial tissue noradrenaline concentration and nerve sprouting (Jayachandran et al. 2000; Chang et al. 2001) . Comparable changes were associated with chronic AF in humans, including hyperinnervation and increased tissue noradrenaline (Gould et al. 2006) . Increases in atrial tissue adrenergic innervation and associated catecholamines, particularly of a spatially heterogeneous nature, may favour reentry and/or nonreentry.
Clinical use of β-blockers in AF: when and how is adrenergic control effective?
In patients with AF, β-blockers are used mainly to prevent the rapidly activating atria from stimulating the ventricles at excessively high rates. The mechanism is a slowing of atrioventricular (AV) nodal conduction, associated with increased AV nodal ERP and AH interval (Prystowsky 1988) . This probably involves an antiadrenergic effect on I CaL , which is the main inward current in AV node (Workman et al. 1999) . β-Blockers can also prevent AF, convert it to sinus rhythm, or maintain sinus rhythm after it is restored, depending on β-blocker type and cardiac pathology (Lopez-Sendon et al. 2004 ). For example, in patients with CHF, β 1 -blockade substantially reduced the incidence of AF (Van Veldhuisen et al. 2006) . In patients with LVSD following MI, carvedilol, a β 1 -, β 2 -, and α 1 -antagonist, also substantially reduced the incidence of AF/ atrial flutter (McMurray et al. 2005) . β-Blockers reduced the incidence of AF following cardiac surgery (Mathew et al. 2004; Workman et al. 2006) , and postsurgery β-blocker withdrawal increased it (Mathew et al. 2004) . Carvedilol was more effective than a β 1 -blocker (Haghjoo et al. 2007) , perhaps by decreasing I Kur and I TO (Deng et al. 2007) . A β 1 -blocker also caused a moderate reduction in the incidence of paroxysmal AF (Steeds et al. 1999) or of relapse into AF after electrical or pharmacological cardioversion (Kuhlkamp et al. 2000) . Acute β-selective blockade has little or no effect on atrial electrophysiology in the absence of catecholamines (Wit et al. 1975) , and catecholamine levels were not affected by β-blockade in patients (Bolger et al. 2002) . Therefore, the relatively high efficacy of β-blockers to prevent AF associated with elevated adrenergic tone, as occurs in, e.g. CHF (Bolger et al. 2002) or postsurgery (Engelman et al. 1983) , suggests an antiadrenergic suppression of proarrhythmic effects of catecholamines. The electrophysiological mechanisms are likely to be multiple. For example, a reduction by atenolol of cAMP-stimulated I CaL in human atrial cells (Mewes et al. 1993 ) might suppress arrhythmic activity that involves increased CICR. A similar mechanism might account for an acute effect of propranolol to suppress either noradrenalineinduced AA in canine atrial fibres (Davis 1975) , or AT in a CHF-remodelled atrium that produced spontaneous depolarisations (Stambler et al. 2003) . A reduction of ISOstimulated I Kur by propranolol in human atrial cells (Li et al. 1996 ) is consistent with its acute effect to moderately increase atrial APD 90 and ERP in patients (Shimizu et al. 1994b) . That might moderately increase wavelength, although acute propranolol did not affect wavelength in canine atrium (Rensma et al. 1988) , or ERP in AFremodelled goat atrium (Wijffels et al. 1997) . Furthermore, an acute suppression by atenolol of autonomic nerve stimulation-induced PV arrhythmic activity in dogs might involve inhibition of AA or reentry, as well as afterdepolarisations (Patterson et al. 2005) . Moreover, atrial antiarrhythmic effects of β-blockers may also involve another type of electrophysiological remodelling: that from the long-term drug treatment.
Atrial remodelling by chronic β-blocker treatment
The long-term use of β-blockers causes adaptive changes in, e.g. atrial electrophysiology, contraction, and adrenoceptors, which may contribute to the effects of these drugs on AF. Such "pharmacological remodelling" (Workman et al. 2003b ) was originally demonstrated in rabbits (Raine and Vaughan Williams 1981) . Treatment with either a β 1 -or a mixed β-blocker increased APD in atrium (Fig. 3a) and ventricle, maximally after 6 days in atrium (Raine and Vaughan Williams 1981) . This was an adaptation to the treatment, not effects due to the presence of the drugs, because the APD was recorded at a sufficient time after the last dose for the drugs to have been eliminated from the body. That was confirmed in plasma and tissue samples (Raine and Vaughan Williams 1980) . Subsequent studies in atrial cells from patients in sinus rhythm showed that β 1 -blocker treatment for ≥7 days was associated with an increased APD 90 and ERP (Workman et al. 2003b (Workman et al. , 2006 Redpath et al. 2006; Fig. 3b ) and a decreased I TO (Workman et al. 2003b; Marshall et al. 2009 ) and I K1 (Marshall et al. 2006) . The atrial ERP correlated with β-blocker dose (Workman et al. 2008) . The I TO reduction, as found also in atrial cells from rabbits treated with carvedilol (Cao et al. 2006) , did not involve altered voltage dependency, kinetics, or channel expression (Marshall et al. 2009 ). I CaL did not change, either in amplitude (Workman et al. 2003b (Workman et al. , 2006 Pau et al. 2003 Pau et al. , 2007 Redpath et al. 2006) , activation voltage dependence , single channel gating (Klein et al. 2003) , or expression (Grammer et al. 2001) . That is consistent with a lack of change in APD 50 (Workman et al. 2003b; Redpath et al. 2006 ). I SUS also was unaffected (Workman et al. 2003b; Marshall et al. 2006) . The human atrial electrophysiological changes most likely reflect an adaptation to the treatment also, because recordings were made in the presumed absence of residual β-blocker (cells had been isolated and washed), and the APD 90 and ERP increases were independent of various clinical covariables (Workman et al. 2003b (Workman et al. , 2006 . No reports on atrial Ca 2+ i
were found, but chronic β 1 -blockade in mice increased a HF-impaired ventricular Ca 2+ i transient (Bartholomeu et al. 2008 ). Catecholamine-induced arrhythmic contractions in human atrial muscles were exacerbated by β-blocker therapy (Kaumann and Sanders 1993) , probably not involving any altered I CaL response to β-stimulation . Nevertheless, human atrial β-receptors, perhaps predominantly β 1 , were upregulated by β-blocker therapy (Hedberg et al. 1985; Michel et al. 1988) , possibly related to a reduction in adrenergic nerve activity (Raine and Chubb 1977) . The β-blocker remodelling of atrial APD 90 and ERP might be expected to increase reentry wavelength and thus contribute to antifibrillatory actions of β-blockers. However, the net effect of β-blockers in patients undergoing treatment is likely to include antiadrenergic effects in an atrium remodelled by the chronic treatment, as well as by underlying cardiac disease.
Concluding remarks and potential future directions
The evidence in this review suggests that AF that is caused by adrenergic stimulation results, in large part, from a promotion of atrial arrhythmic activity involving increased I CaL and Ca 2+ i , rather than from any effect on action potential terminal repolarisation or ERP. The suppression of AF by treatment with β-blockers is likely to involve attenuation of such arrhythmic activity, potentially coupled with an ERP-prolonging adaptation to the treatment, socalled pharmacological remodelling. It is hoped that an improved understanding of the involvement of the adrenergic system and its control in basic mechanisms of AF under differing cardiac pathologies will lead to better pharmacological treatments. However, there are numerous and wide gaps in our knowledge, particularly pertaining to human atrium, which suggest avenues for further research. pharmacological therapy is the mainstay of treatment for AF. New anti-AF drugs in development include "atrialselective compounds", and "multi-channel blockers" such as dronedarone (Ehrlich and Nattel 2009 ). This drug's antiadrenergic activity may be expected to contribute to its antiarrhythmic efficacy. Yeh YH, Wakili R, Qi XY et al (2008) Yue L, Feng J, Li GR et al (1996) 
